Penserra Capital Management LLC Verve Therapeutics, Inc. Transaction History

Penserra Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$11.42 - $20.82 $15,417 - $28,107	1,350 Added 18.77%	8,544 $113,000
Q2 2023 Aug 11, 2023	BUY	$13.34 - $19.9 $15,260 - $22,765	1,144 Added 18.91%	7,194 $134,000
Q1 2023 Apr 24, 2023	BUY	$14.3 - $24.01 $6,292 - $10,564	440 Added 7.84%	6,050 $87,000
Q4 2022 Feb 13, 2023	SELL	$17.85 - $40.7 $144,745 - $330,036	-8,109 Reduced 59.11%	5,610 $108,000
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $169,100 - $448,880	10,819 Added 373.07%	13,719 $471,000
Q2 2022 Aug 15, 2022	BUY	$11.14 - $23.17 $9,580 - $19,926	860 Added 42.16%	2,900 $44,000
Q1 2022 May 13, 2022	BUY	$20.92 - $39.36 $42,676 - $80,294	2,040 New	2,040 $46,000

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $291M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.